FDA approves Aristada Inito for the initiation of Aristada for schizophrenia
Novel regimen enables physicians to fully dose up to two…
Novel regimen enables physicians to fully dose up to two months of Aristada treatment on day one...
List view / Grid view
Novel regimen enables physicians to fully dose up to two…
Novel regimen enables physicians to fully dose up to two months of Aristada treatment on day one...
The FDA has accepted for review the New Drug Application…
The FDA has accepted for review the New Drug Application for ALKS 5461, a novel, once-daily, oral investigational medicine for the adjunctive treatment of major depressive disorder ...